Studies conducted by the National Center for Oncological Investigations found that the thermozolomite together with the dianhydrogalactitol retards the crime of the cells
The combined therapies are one of the great revolutions for the patients, assuring the experts. Advances in the molecular biology compensation of tumors allow the appearance of new therapies to combat tumors.
The investigators analyzed the dianhidrogalactitol, a chemotherapeutic capability to overcome the hematoencephalic barrier and align the central nervous system to induce dementia in the DNA of tumor cells.
The results demonstrated that the combination of the pharmacists actuarial actuation on tumor cells reducing their growth rate. Además, the experts creen that he dianhidrogalactitol it can be an effective treatment for the resistance of tumors.
This pharmacy is approved in China for the treatment of acute myeloid leukemia and pulmonary cancer. It is currently being tested in clinical trials for gliomas and other types of cancer such as ovarian cancer.
Currently for the treatment of glioblastomas combine radiotherapy with chemotherapy agent temozolomida. This medicine produces data on the genetic material of the tumor cells, which induces them to collapse and cell death.
Treatment of tumors that are vuelven resistant to the temozolomida y el washed continues to grow while treating it. The investigator Massimo Squatrito assured that the glioblastomas I have the most common tumors because they do not have effective treatments.
The origin of the resistance of tumors to the temozolomida have to go to the glioblastomas Produces genomic reordinations in the DNA repair gene MGMT increased its production, repairing the day and canceling the effects of the treatment.